“There is a new kid on the block to rival E. Coli, CHO and yeast,” says Dyadic International as it collaborates to widen the use of its C1 expression tech.
A warning letter at manufacturing partner Celltrion could delay approvals of the potential migraine prevention monoclonal antibody fremanezumab and two biosimilar candidates, says Teva.
Catalent has partially attributed a 26% year-on-year growth in its Drug Delivery Solutions segment to the acquisition of Cook Pharmica, which closed in the quarter.
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems.
Adaptimmune Therapeutics has manufactured the first SPEAR-T cells for a patient at its Navy Yard facility, which will be the primary site for its future manufacturing requirements.
Partner Therapeutics (PTx) has acquired the rights to Sanofi’s FDA-approved human growth factor Leukine along with a dedicated manufacturing plant in Washington state.
Amgen has announced plans for a US biomanufacturing facility, similar to its flexible and single-use Singapore plant, as part of $3.5bn freed through tax reforms.
The need for CDMOs with commercial gene therapy capacity is growing says Fujilfilm Diosynth Biotechnologies, which has opened an 80,000 square-foot plant in Texas.
Clover Biopharmaceuticals will adopt GE Healthcare’s centrally automated FlexFactory platform at its facility in Zhejiang, China where it plans to make a biosimilar to Amgen’s Enbrel.
Novartis will install Berkeley Lights’ Beacon antibody discovery technology, the sixth large pharmaceutical firm to adopt the platform in less than a year.
